Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

September 24, 2015

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Lifileucel

A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.

Trial Locations (57)

3010

Inselspital, Bern

4103

Universitätsklinikum Leipzig, Leipzig

6720

Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ, Szeged

10016

New York University Langone Medical Center, New York

10060

Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia, Candiolo

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh

19701

Thomas Jefferson University, Philadelphia

20141

Istituto Europeo di Oncologia, Milan

23298

Virginia Commonwealth University, Richmond

23538

Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck

28007

Hospital General Universitario Gregorio Marañon, Madrid

28041

Hospital 12 de Octubre, Madrid

28050

HM Centro Integral Oncológico Clara Campal, Madrid

28233

Hospital Universitario Quirónsalud Madrid, Madrid

31008

Clínica Universidad de Navarra, Pamplona

32806

University of Florida Health Cancer Center, Orlando

33081

Centro di Riferimento Oncologico di Aviano, Aviano

33136

University of Miami, Miami

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

33612

University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa

40202

James Graham Brown Cancer Center, Louisville

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Masonic Cancer Center, Minneapolis

69008

Centre Léon Bérard, Lyon

69120

Universitaetsklinikum Heidelberg, Heidelberg

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

72076

Universitaetsklinikum Tuebingen (UKT) - Suedwestdeutschen Tumorzentrum - Zentrum für Neuroonkologie, Tübingen

80049

University of Colorado Cancer Center, Aurora

80131

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli

81675

Klinikum Rechts der Isar der Technischen Universität München, München

87042

Hôpital Dupuytren, Limoges

90048

The Angeles Clinic and Research Institute, Los Angeles

90095

University of California Los Angeles - David Geffen School of Medicine - Westwood Rheumatology, Los Angeles

91052

Universitätsklinikum Erlangen, Erlangen

92093

University of California San Diego Moores Cancer Center, La Jolla

94115

California Pacific Medical Center, San Francisco

94805

Gustave Roussy Cancer Campus, Villejuif

97080

Universitätsklinikum Würzburg, Würzburg

97213

Providence Cancer Center Oncology and Hematology Care Clinic, Portland

98109

Seattle Cancer Care Alliance, Seattle

06510

Yale Cancer Center, New Haven

46202-5116

Indiana University, Indianapolis

07960

Atlantic Health System, Morristown

Unknown

Rutgers University, New Brunswick

Universitätsklinikum Carl Gustav Carus, Dresden

Consorci Hospital General Universitari de València, Valencia

Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie, Lausanne

06120

Universitätsklinikum Halle, Halle

08035

Hospital Universitari Vall d'Hebrón, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

08907

Institut Català d'Oncologia, Barcelona

SW3 6JJ

Royal Marsden NHS Trust, London

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

CB2 0QQ

Addenbrooke's Hospital, Cambridge

W1G 6AD

Sarah Cannon Research Institute London, London

Sponsors
All Listed Sponsors
lead

Iovance Biotherapeutics, Inc.

INDUSTRY